Profile data is unavailable for this security.
About the company
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
- Revenue in USD (TTM)4.15bn
- Net income in USD535.20m
- Incorporated1999
- Employees10.30k
- LocationDexcom Inc6340 Sequence DrSAN DIEGO 92121-4356United StatesUSA
- Phone+1 (858) 200-0200
- Fax+1 (302) 636-5454
- Websitehttps://www.dexcom.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zimmer Biomet Holdings Inc | 7.70bn | 913.40m | 18.53bn | 17.00k | 20.76 | 1.50 | 9.62 | 2.41 | 4.51 | 4.51 | 38.06 | 62.63 | 0.3529 | 0.9622 | 5.17 | 452,852.90 | 4.19 | 2.34 | 4.75 | 2.68 | 71.05 | 71.18 | 11.88 | 7.60 | 1.46 | 6.46 | 0.3665 | 37.52 | 3.85 | -0.7725 | -11.74 | 2.05 | -3.69 | 0.00 |
| Waters Corp | 2.98bn | 657.02m | 20.84bn | 7.60k | 31.79 | 10.62 | 24.49 | 6.99 | 11.02 | 11.02 | 50.04 | 32.98 | 0.6556 | 2.31 | 4.45 | 392,533.30 | 14.44 | 18.41 | 18.02 | 23.46 | 59.27 | 58.71 | 22.02 | 22.81 | 1.28 | 13.77 | 0.426 | 0.00 | 0.0667 | 4.22 | -0.6851 | 1.61 | -2.75 | -- |
| Insulet Corp | 2.20bn | 402.20m | 21.18bn | 3.90k | 54.18 | 15.92 | 43.59 | 9.63 | 5.56 | 5.56 | 29.72 | 18.91 | 0.7161 | 1.49 | 6.08 | 563,820.50 | 13.10 | 6.00 | 15.50 | 7.03 | 70.39 | 67.05 | 18.29 | 9.22 | 3.63 | 49.39 | 0.5603 | 0.00 | 22.07 | 22.92 | 102.76 | 104.84 | -4.75 | -- |
| Steris PLC | 5.46bn | 610.12m | 23.37bn | 17.79k | 38.57 | 3.54 | 21.48 | 4.28 | 6.16 | 6.20 | 55.11 | 67.18 | 0.5148 | 4.87 | 5.32 | 306,938.50 | 5.77 | 5.04 | 6.36 | 5.51 | 44.01 | 43.75 | 11.20 | 10.69 | 1.39 | 12.76 | 0.236 | 37.51 | 6.24 | 12.49 | 10.64 | 8.40 | 11.52 | 8.99 |
| DexCom Inc | 4.15bn | 535.20m | 32.52bn | 10.30k | 63.59 | 14.35 | 42.76 | 7.84 | 1.30 | 1.30 | 10.11 | 5.78 | 0.6269 | 2.89 | 3.89 | 402,718.40 | 8.09 | 8.79 | 12.44 | 11.75 | 60.72 | 64.97 | 12.90 | 14.90 | 1.32 | -- | 0.5246 | 0.00 | 11.34 | 22.27 | 6.41 | 41.63 | 14.79 | -- |
| Agilent Technologies Inc | 6.63bn | 1.17bn | 34.48bn | 18.00k | 29.87 | 5.62 | 23.89 | 5.20 | 4.06 | 4.06 | 23.09 | 21.61 | 0.576 | 3.08 | 5.07 | 370,279.30 | 10.13 | 10.93 | 12.25 | 13.09 | 53.77 | 53.35 | 17.59 | 17.93 | 1.60 | 24.95 | 0.3629 | 21.83 | -4.73 | 4.75 | 3.95 | 3.77 | 19.36 | 7.80 |
| GE HealthCare Technologies Inc | 19.80bn | 2.18bn | 34.83bn | 53.00k | 15.99 | 3.79 | 12.36 | 1.76 | 4.76 | 4.76 | 43.13 | 20.07 | 0.6018 | 5.54 | 4.51 | 373,547.20 | 6.84 | -- | 9.67 | -- | 41.99 | 40.35 | 11.37 | 10.78 | 0.7601 | 8.18 | 0.483 | 1.19 | 0.6138 | 3.41 | 43.48 | 3.82 | 3.91 | -- |
| Resmed Inc | 5.02bn | 1.31bn | 37.68bn | 9.98k | 28.85 | 6.79 | 24.77 | 7.50 | 8.91 | 8.91 | 34.05 | 37.83 | 0.6983 | 2.45 | 5.65 | 503,159.20 | 18.26 | 14.24 | 20.73 | 16.53 | 58.76 | 56.85 | 26.15 | 20.35 | 2.49 | 58.86 | 0.1082 | 32.62 | 10.95 | 12.44 | 13.75 | 19.98 | 8.23 | 5.89 |
| IDEXX Laboratories Inc | 3.93bn | 894.97m | 43.99bn | 11.00k | 50.55 | 30.50 | 42.75 | 11.19 | 10.82 | 10.82 | 47.53 | 17.93 | 1.20 | 3.87 | 6.81 | 357,439.60 | 27.26 | 28.11 | 40.01 | 42.15 | 61.28 | 59.56 | 22.76 | 22.19 | 0.8111 | 53.37 | 0.3937 | 0.00 | 6.46 | 10.12 | 5.07 | 15.73 | -3.35 | -- |
| Edwards Lifesciences Corp | 5.54bn | 1.44bn | 45.05bn | 15.80k | 31.68 | 4.44 | 28.54 | 8.13 | 2.42 | 7.00 | 9.31 | 17.28 | 0.4867 | 0.984 | 7.45 | 350,557.00 | 12.63 | 14.52 | 14.28 | 16.61 | 79.38 | 79.01 | 25.95 | 25.54 | 3.66 | -- | 0.0554 | 0.00 | 8.57 | 4.58 | 14.55 | 5.94 | 0.2857 | -- |
| Veeva Systems Inc | 2.86bn | 780.66m | 46.46bn | 7.29k | 60.31 | 7.46 | 56.56 | 16.27 | 4.71 | 4.71 | 17.25 | 38.11 | 0.4093 | -- | 6.06 | 391,622.10 | 11.19 | 11.33 | 13.85 | 14.35 | 75.50 | 72.60 | 27.34 | 23.96 | -- | -- | 0.00 | 0.00 | 16.20 | 19.99 | 35.84 | 18.85 | 36.56 | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 45.60m | 11.67% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 24.72m | 6.33% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 16.68m | 4.27% |
| Baillie Gifford & Co.as of 31 Mar 2025 | 14.18m | 3.63% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 12.04m | 3.08% |
| Jennison Associates LLCas of 31 Mar 2025 | 10.52m | 2.69% |
| Sands Capital Management LLCas of 31 Mar 2025 | 10.41m | 2.67% |
| Geode Capital Management LLCas of 31 Mar 2025 | 10.41m | 2.66% |
| TIAA-CREF Investment Management LLCas of 31 Mar 2025 | 6.39m | 1.63% |
| UBS Asset Management Switzerland AGas of 31 Mar 2025 | 5.57m | 1.43% |
